Corcept's Phase III trial of ovarian cancer therapy shows PFS improvement [Yahoo! Finance]
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Canaccord Genuity Group Inc. from $130.00 to $142.00. They now have a "buy" rating on the stock.
Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday? [Yahoo! Finance]
Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip [Yahoo! Finance]
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Truist Financial Co. from $76.00 to $150.00. They now have a "buy" rating on the stock.